(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +52 locations
Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
Recruiting
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Lowering blood sugar levels after a meal is expected to have a positive effect on preventing metabolic and cardiovascular diseases and improving the metabolic control of those who already suffer from these conditions. The aim of this study is to investigate the effect of Oligomate® (beta-galacto-oli... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: University of Aberdeen, Rowett Institute, Aberdeen, Not set
Conditions: Postprandial Hyperglycemia, Hyperinsulinemia
CNGB1 and Allied Disorders
Recruiting
Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystro... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Dr. Stephen H. Tsang, New York, New York +5 locations
Conditions: Retinitis Pigmentosa Associated With CNGB1 Mutations
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
Recruiting
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +7 locations
Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
The Effects of Moderate Intensity Cycle Ergometer vs. Treadmill Training on Physiological Resilience in Older Adults
Recruiting
Government guidelines suggest that we should all take part in approximately two and a half hours each week of moderate-intensity aerobic exercise. Older adults are particularly important as their overall health may decline as they get older. Therefore, exercising is important especially for older adults to improve heart and muscle health and functioning in carrying out tasks of daily living. The overall effects of aging on the body can make people less likely to withstand challenges to the body... Read More
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
04/24/2025
Locations: The University of Nottingham/Medical School, Derby, Derbyshire
Conditions: Older People
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment
Recruiting
The goal of this randomized controlled trial is to determine whether the digital health app Five Lives MED can improve cognitive function in people with mild cognitive impairment (MCI). The main question it aims to answer is: Can 12 weeks of using Five Lives MED improve global cognitive function in people diagnosed with MCI? Researchers will compare with a control group who receives a leaflet with standard health information. Participants in the intervention group will be asked to use the Fiv... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/24/2025
Locations: Hôpital Broca, Service de gériatrie Hôpitaux Universitaire Paris Centre, Université Paris Cité, Paris, Ile de France +6 locations
Conditions: Mild Cognitive Impairment
Co-producing a Novel Model an Outcome Framework for the Implementation of Falls Management in Care Home Settings.
Recruiting
AIM: To co-produce a novel model for implementation of falls management for older people living in care homes SECONDARY OBJECTIVES Component One Objectives: Primary :To co-produce a novel model for the implementation of falls management in care homes Secondary * To facilitate a series of co-production workshops with representation of key stakeholders * To co-produce a novel implementation model for falls management * To co-produce an outcomes framework to evaluate the implementation model *... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Nottingham, Nottingham, Not set
Conditions: Old Age, Long Term Care Facility, Fall Prevention
Characterisation of Skin Microstructure Under Normal and Atrophied States
Recruiting
Skin dermatoses are a major health concern around the world, with heavy economic, social, and psychological burdens. Due to their chronic and incurable nature, they are serious diseases that cause physical pain in patients and reduced quality of life. Atopic dermatitis is the most common inflammatory skin disease with a prevalence of almost 20% in children and 10% in adults. Current therapies are designed to control the condition rather than cure it. Therefore, these therapies are lifelong and,... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
04/24/2025
Locations: Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS FT, Sheffield, South Yorkshire
Conditions: Atopic Dermatitis
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Recruiting
This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
04/24/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +7 locations
Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
First in Human Study of T3P-Y058-739 (T3P)
Recruiting
This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
04/24/2025
Locations: Vall d'Hebron Institute of Oncology, Barcelona, Not set +10 locations
Conditions: Advanced Solid Tumor
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Shiley Eye Institute, San Diego, California +12 locations
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Transcutaneous Vagus Nerve Stimulation in Aphasia After Stroke
Recruiting
Aphasia is an acquired language disorder. Stroke is the most common cause of aphasia, which affects 30% of stroke survivors. Speech and Language Therapy (SLT) can help people with aphasia but it may not be provided at the required intensity. Access to therapy is often limited after the first few months following stroke. People with aphasia can improve with therapy many years after stroke but these benefits have not been found to translate to day to day conversation. Transcutaneous Vagus Nerve S... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set
Conditions: Aphasia, Chronic Stroke